Your browser doesn't support javascript.
loading
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich, K; Blauvelt, A; Armstrong, A; Langley, R G; Fox, T; Huang, J; Papavassilis, C; Liang, E; Lloyd, P; Bruin, G.
  • Reich K; Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany.
  • Blauvelt A; Oregon Medical Research Center, Portland, OR, U.S.A.
  • Armstrong A; University of Southern California, Los Angeles, CA, U.S.A.
  • Langley RG; Dalhousie University, Halifax, NS, Canada.
  • Fox T; Novartis Pharma AG, Basel, Switzerland.
  • Huang J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A.
  • Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
  • Liang E; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Lloyd P; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Bruin G; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Br J Dermatol ; 176(3): 752-758, 2017 Mar.
Article en En | MEDLINE | ID: mdl-27518376
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Psoriasis / Fármacos Dermatológicos / Anticuerpos Monoclonales Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Psoriasis / Fármacos Dermatológicos / Anticuerpos Monoclonales Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article